| Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s T Oba, MD Long, T Keler, HC Marsh, H Minderman, SI Abrams, S Liu, F Ito Nature communications 11 (1), 5415, 2020 | 102 | 2020 |
| T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors T Yamauchi, T Hoki, T Oba, V Jain, H Chen, K Attwood, S Battaglia, ... Nature communications 12 (1), 1402, 2021 | 99 | 2021 |
| CX3CR1–CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment T Yamauchi, T Hoki, T Oba, H Saito, K Attwood, MS Sabel, AE Chang, ... JCI insight 5 (8), 2020 | 59 | 2020 |
| ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines T Oba, H Izumi, K Ito Oncotarget 7 (43), 70011, 2016 | 40 | 2016 |
| Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer T Oba, K Maeno, D Takekoshi, M Ono, T Ito, T Kanai, K Ito BMC cancer 20, 1-10, 2020 | 32 | 2020 |
| Breast metastases of gastric signet-ring cell carcinoma: a report of two cases and review of the literature A Iesato, T Oba, M Ono, T Hanamura, T Watanabe, T Ito, T Kanai, ... OncoTargets and therapy, 91-97, 2014 | 29 | 2014 |
| In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic … T Oba, K Makino, R Kajihara, T Yokoi, R Araki, M Abe, H Minderman, ... Journal for immunotherapy of cancer 9 (5), 2021 | 27 | 2021 |
| Prognostic nutritional index is superior to neutrophil-to-lymphocyte ratio as a prognostic marker in metastatic breast cancer patients treated with eribulin T Oba, K Maeno, M Ono, T Ito, T Kanai, K Ito Anticancer Research 41 (1), 445-452, 2021 | 20 | 2021 |
| A critical role of CD40 and CD70 signaling in conventional type 1 dendritic cells in expansion and antitumor efficacy of adoptively transferred tumor-specific T cells T Oba, T Hoki, T Yamauchi, T Keler, HC Marsh, X Cao, F Ito The Journal of Immunology 205 (7), 1867-1877, 2020 | 20 | 2020 |
| Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer M Amitani, T Oba, N Kiyosawa, H Morikawa, T Chino, A Soma, T Shimizu, ... BMC cancer 22 (1), 327, 2022 | 18 | 2022 |
| Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling K Makino, MD Long, R Kajihara, S Matsueda, T Oba, K Kanehira, S Liu, ... Journal for immunotherapy of cancer 10 (1), 2022 | 18 | 2022 |
| Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis T Oba, T Chino, A Soma, T Shimizu, M Ono, T Ito, T Kanai, K Maeno, K Ito Endocrine Journal 67 (12), 1215-1226, 2020 | 18 | 2020 |
| Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition T Oba, KI Ito Oncotarget 9 (33), 22986, 2018 | 18 | 2018 |
| The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time M Ono, T Oba, T Shibata, K Ito Journal of Cancer Research and Clinical Oncology 147, 3211-3224, 2021 | 15 | 2021 |
| Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer T Watanabe, T Oba, K Tanimoto, T Shibata, S Kamijo, K Ito PLoS One 16 (6), e0252822, 2021 | 14 | 2021 |
| HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells T Oba, M Ono, H Matoba, T Uehara, Y Hasegawa, K Ito Breast Cancer Research and Treatment 186, 37-51, 2021 | 14 | 2021 |
| CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1+ CD8+ T cells T Yamauchi, T Hoki, T Oba, R Kajihara, K Attwood, X Cao, F Ito Cancer Immunology, Immunotherapy 71 (1), 137-151, 2022 | 13 | 2022 |
| Neoadjuvant In Situ Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors T Oba, R Kajihara, T Yokoi, EA Repasky, F Ito Cancer research 81 (24), 6183-6195, 2021 | 12 | 2021 |
| FGF2-FGFR1 pathway activation together with thymidylate synthase upregulation is induced in pemetrexed-resistant lung cancer cells K Miura, T Oba, K Hamanaka, K Ito Oncotarget 10 (11), 1171, 2019 | 12 | 2019 |
| A case of arteritis that developed after pegfilgrastim administration during chemotherapy for breast cancer T Chino, T Oba, K Yamamoto, D Takekoshi, A Iesato, T Ito, T Kanai, ... Gan to Kagaku Ryoho. Cancer & Chemotherapy 45 (12), 1771-1774, 2018 | 12 | 2018 |
Fumito ItoUniversity of Southern California在 med.usc.edu 的电子邮件经过验证
